Roundtable: February 23, 2026
Patience in the Purge: 14 alerts, 0 new trades. NVO removed. CPRT and V GTCs filled. System executing while the market bleeds.
Regime Warning: Active
The broad selloff continues. Portfolio at -7.8% vs VOO -1.3%. Alpha: -6.5%. This is an internal bear market for quality compounders while narrow AI leadership props up the index. Track 2 entries suppressed. Resting GTCs are doing the work.
Portfolio Snapshot
| Metric | Value |
|---|---|
| Portfolio Value | $36,886 (per tracker — excludes unrecorded fills below) |
| VOO Return | -1.3% |
| Portfolio Return | -7.8% |
| Alpha vs VOO | -6.5% |
| Positions | 11 stocks (after CPRT and V fills) |
GTC Fills Since Last Session
Multiple GTC orders filled while the system was unattended. This is exactly how the system is supposed to work — resting orders at predetermined targets, letting Mr. Market come to us.
| Date | Ticker | Shares | Price | Amount | Notes |
|---|---|---|---|---|---|
| Jan 30 | TYL | 2 | $380.02 | $760 | GTC fill. Now 6 shares total. |
| Jan 30 | ROP | 2 | $363.29 | $727 | GTC fill. Now 29 shares total. |
| Feb 3 | FICO | 1 | $1,400.03 | $1,400 | GTC fill. Now 2 shares, avg ~$1,512. |
| Feb 20 | CPRT | 60 | $34.40 | $2,064 | New position. Filled during earnings selloff. |
| Feb 23 | V | 3 | $309.51 | $929 | GTC fill. Now 6 shares total. |
Total deployed: $5,880 across 5 fills. The system is working as designed — patient GTCs catching falling prices without emotional decision-making.
Thesis Removed: NVO (Novo Nordisk)
NVO dropped another -16.4% today to $39.63, continuing a structural collapse. The Auditor recommended BUY at 71%. The Narrator flagged it as a falling knife at 55%. Both overruled.
The Arbiter ruled on Feb 6: NVO’s thesis is broken. Lilly is winning on efficacy (20.2% vs 13.7% weight loss), pricing power, and patent protection. NVO guided for 5–13% sales decline in 2026. This is not a tantrum. Removed from active watchlist.
Thesis Watch: FICO (Fair Isaac) — Weakening
FICO dropped -5.1% today to $1,281.64, near its 52-week low of $1,268. We now own 2 shares at an average cost of ~$1,512 — currently down ~15%.
The second share filled via GTC at $1,400.03 on Feb 3, before we discovered the FHFA/VantageScore regulatory threat on Feb 12. That’s not a bad decision — it’s new information arriving after disciplined entry. But it stings, and it’s a reminder that GTCs can fill into deteriorating theses if we’re not monitoring.
The business is still executing: Q1 2026 revenue up 16% YoY, EPS beat by 3.7%, Scores segment up 29%, 54% operating margins, Mortgage Direct Licensing Program covering 70–80% of the reseller market.
But the monopoly moat is under regulatory attack: FHFA eliminated the FICO requirement from the GSE lending guide. VantageScore 4.0 is now an approved alternative. 134 insider sells, 0 insider buys. Full-year guidance of $2.35B trails Street estimates by 4–6%.
Arbiter ruling: Thesis remains WEAKENING. 90-day review clock active from Feb 12. Hold 2 shares. Do NOT add. The question “are we directionally right but too early?” is valid — at 24x forward on a business growing 16%, FICO could be genuinely cheap if VantageScore adoption stays single-digit. But we don’t risk new capital until the regulatory trajectory clarifies.
Thesis Check Needed: CPRT (Copart)
Our largest new fill — 60 shares @ $34.40 on Feb 20 — came the same day CPRT reported a Q2 earnings miss. Revenue of $1.12B declined 3.6% YoY and missed estimates. EPS of $0.36 missed the $0.39 consensus by 7.5%. Operating margin fell to 34.7% from 36.6%. JPMorgan cut their price target to $34. Barclays has an underweight at $32.
The bull case: Free cash flow is actually up significantly — $485M year-to-date, trending toward ~$970M for the full year. Capex was cut nearly in half. The salvage auction model is counter-cyclical long-term (more accidents = more volume). The stock is 43% below its 52-week high.
The concern: Revenue declining 3.6% YoY with shrinking margins is new. This needs honest scrutiny, not a rubber stamp. Is this a temporary volume dip, or is the salvage market structurally softening?
Arbiter ruling: Hold the position. Flag for full thesis review next session. The fill was disciplined (GTC at target), but post-fill earnings require us to re-evaluate. ADD target of $32 should NOT be deployed until the thesis check clears.
AI Analyst Conflicts & Resolutions
FICO: Auditor vs Arbiter
The Auditor recommended ADD at 78% confidence, citing valuation below historical average. Overruled. The Feb 12 thesis downgrade to WEAKENING takes precedence. Same “cheap + quality = buy” pattern-matching that nearly led us into NVO.
NVO: Auditor vs Everyone
The Auditor recommended BUY at 71% confidence. Overruled. Thesis is broken. The Auditor needs to incorporate thesis status into its rule check — “rules satisfied” is meaningless when the thesis is broken.
CPRT: All Initially Agreed — Now Needs Revisiting
The Narrator called CPRT the “vulture of the insurance industry” at 85% confidence. Three days later the company missed on revenue, earnings, and margins. Confidence levels mean nothing if the data changes. Flag for review.
Candidates
V — Visa ($306.52, GTC filled today)
Catalyst: Payment volume slowdown fears. Down -4.5%.
Fill: 3 shares @ $309.51. Now own 6 shares total.
Decision: FILLED — Thesis intact. Payment network duopoly moat. Wait for ADD target $300.
MCO — Moody’s ($437.11, Hold Zone)
Decision: NONE — Own 6 shares. Wait for ADD target $430.
JKHY — Jack Henry ($155.68, Hold Zone)
Decision: NONE — Own 10 shares. Wait for ADD target $150.
VRSN, BAC, WM, TYL, ROP, MSFT, IDXX, RSG
All NONE. GTCs working where applicable. Hold zones respected. No action required.
Final Decisions
| Ticker | Action | Track | Thesis | Notes |
|---|---|---|---|---|
| NVO | REMOVED | 2 | Broken | Removed from active watchlist. |
| CPRT | FILLED | 3 | Intact (review) | 60 shares @ $34.40. Post-fill earnings miss. Thesis check needed. |
| V | FILLED | 3 | Intact | 3 shares @ $309.51. Now 6 shares total. |
| FICO | NONE | 3 | Weakening | Own 2 shares (avg ~$1,512). 90-day review active. Do not add. |
| All others | NONE | 3 | Intact | GTCs working. Hold zones respected. |
The Bigger Picture
On Targets and the New World
Multiple GTC orders filled at targets that were set in a different market regime. FICO’s target assumed an unchallenged monopoly. CPRT’s target assumed revenue growth, not decline. TYL’s target assumed premium valuations for government software before AI disruption fears.
Being “directionally right but too early” is the cost of systematic investing during regime transitions. The system caught us falling prices — which is what it’s designed to do — but the world shifted underneath some of those targets.
Next session priority: A full target review. Position by position, ask: “Given what we know now, would we set the same START and ADD targets?” Some targets may need to be lowered. Some positions may need their ADD orders paused. The system is sound — but the inputs need to reflect current reality, not last quarter’s assumptions.
On Getting Cooked
The portfolio is down 7.8% while VOO is down only 1.3%. The gap hurts. But this is a five-week-old experiment accumulating de-rated moats during a narrow-leadership market. The system was designed for this: suppress emotional buying, let GTCs work, preserve cash for deeper legs.
Every position except FICO has an intact thesis. CPRT needs a post-earnings review. The regime warning is firing correctly. The rules are being followed. Abandoning the system now locks in the pain and misses the recovery.
The question is not “can we beat the market” — it is “are we executing our rules?” The answer is yes.
Calendar Flags
CPRT: Full thesis review needed next session. Revenue decline + margin compression post-fill.
FICO: 90-day review clock from Feb 12. Check VantageScore GSE adoption by mid-May. Next earnings May 6.
V: New fill today. Monitor payment volume trends. ADD target $300.
Target Review: Highest priority for next session. Reassess all START and ADD targets against current fundamentals.
Tracker Update: 3 unrecorded fills need ingestion (FICO Feb 3, TYL Jan 30, ROP Jan 30).